Cite
Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
MLA
Diana I. Albu, et al. “Combination of EP4 Antagonist and Checkpoint Inhibitors Promotes Anti-Tumor Effector T Cells in Preclinical Tumor Models.” Journal for ImmunoTherapy of Cancer, vol. 3, Nov. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....42dfeca48546b1d458fab424d60b1373&authtype=sso&custid=ns315887.
APA
Diana I. Albu, Mary Woodall-Jappe, Natalie C. Twine, Xingfeng Bao, Kuan-Chun Huang, Jiayi Wu, & Kenichi Nomoto. (2015). Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models. Journal for ImmunoTherapy of Cancer, 3.
Chicago
Diana I. Albu, Mary Woodall-Jappe, Natalie C. Twine, Xingfeng Bao, Kuan-Chun Huang, Jiayi Wu, and Kenichi Nomoto. 2015. “Combination of EP4 Antagonist and Checkpoint Inhibitors Promotes Anti-Tumor Effector T Cells in Preclinical Tumor Models.” Journal for ImmunoTherapy of Cancer 3 (November). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....42dfeca48546b1d458fab424d60b1373&authtype=sso&custid=ns315887.